Tags

Type your tag names separated by a space and hit enter

Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
Vaccine. 2010 Jan 08; 28(3):714-23.V

Abstract

BACKGROUND

Between July 1997 and April 1998, Canadian public health agencies switched from the whole cell vaccine to the acellular vaccine for pertussis immunization. The acellular vaccine provided better efficacy and fewer adverse events than the whole cell vaccine did.

OBJECTIVE

To determine the economic impact of replacing the whole cell vaccine with an acellular vaccine in Canada.

METHODS

A decision analytic model was developed comparing costs and outcomes of pertussis vaccination for Canadian children born in the years 1991-2004. Effectiveness was measured as number of avoided pertussis cases as well as the number of avoided hospital admissions. Incremental costs per avoided pertussis case and per avoided hospital admission were calculated for Ministry of Health (MoH) and societal (SOC) perspectives. Various one-way sensitivity analyses as well as a Monte Carlo simulation were performed by varying key model parameters.

RESULTS

The switch in immunization programs resulted in an incremental cost to the MoH of CAD $108 per pertussis case avoided (CAD $0.96 per child-year). From the SOC perspective, there was a savings of CAD $184 per pertussis case avoided (CAD $0.13 per child-year). The one-way sensitivity analyses provided incremental cost-effective ratios (ICERs) ranging from an incremental cost of CAD $1034 per avoided pertussis case from the MoH perspective to a saving of CAD $1583 per avoided case from the SOC perspective. The Monte Carlo simulation confirmed the robustness of these results.

CONCLUSIONS

Pertussis vaccination with AcE was cost-saving from the societal perspective and cost-effective from the Ministry of Health perspective.

Authors+Show Affiliations

PharmIdeas Research and Consulting Inc., 1175 North Service Road West, Suite 211, Oakville, ON, Canada.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19895923

Citation

Iskedjian, Michael, et al. "Economic Impact of the Introduction of an Acellular Pertussis Vaccine in Canada: a 6-year Analysis." Vaccine, vol. 28, no. 3, 2010, pp. 714-23.
Iskedjian M, De Serres G, Einarson TR, et al. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis. Vaccine. 2010;28(3):714-23.
Iskedjian, M., De Serres, G., Einarson, T. R., & Walker, J. H. (2010). Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis. Vaccine, 28(3), 714-23. https://doi.org/10.1016/j.vaccine.2009.10.079
Iskedjian M, et al. Economic Impact of the Introduction of an Acellular Pertussis Vaccine in Canada: a 6-year Analysis. Vaccine. 2010 Jan 8;28(3):714-23. PubMed PMID: 19895923.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis. AU - Iskedjian,Michael, AU - De Serres,Gaston, AU - Einarson,Thomas R, AU - Walker,John H, Y1 - 2009/11/04/ PY - 2009/09/04/received PY - 2009/10/13/accepted PY - 2009/11/10/entrez PY - 2009/11/10/pubmed PY - 2010/2/4/medline SP - 714 EP - 23 JF - Vaccine JO - Vaccine VL - 28 IS - 3 N2 - BACKGROUND: Between July 1997 and April 1998, Canadian public health agencies switched from the whole cell vaccine to the acellular vaccine for pertussis immunization. The acellular vaccine provided better efficacy and fewer adverse events than the whole cell vaccine did. OBJECTIVE: To determine the economic impact of replacing the whole cell vaccine with an acellular vaccine in Canada. METHODS: A decision analytic model was developed comparing costs and outcomes of pertussis vaccination for Canadian children born in the years 1991-2004. Effectiveness was measured as number of avoided pertussis cases as well as the number of avoided hospital admissions. Incremental costs per avoided pertussis case and per avoided hospital admission were calculated for Ministry of Health (MoH) and societal (SOC) perspectives. Various one-way sensitivity analyses as well as a Monte Carlo simulation were performed by varying key model parameters. RESULTS: The switch in immunization programs resulted in an incremental cost to the MoH of CAD $108 per pertussis case avoided (CAD $0.96 per child-year). From the SOC perspective, there was a savings of CAD $184 per pertussis case avoided (CAD $0.13 per child-year). The one-way sensitivity analyses provided incremental cost-effective ratios (ICERs) ranging from an incremental cost of CAD $1034 per avoided pertussis case from the MoH perspective to a saving of CAD $1583 per avoided case from the SOC perspective. The Monte Carlo simulation confirmed the robustness of these results. CONCLUSIONS: Pertussis vaccination with AcE was cost-saving from the societal perspective and cost-effective from the Ministry of Health perspective. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/19895923/Economic_impact_of_the_introduction_of_an_acellular_pertussis_vaccine_in_Canada:_a_6_year_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(09)01609-0 DB - PRIME DP - Unbound Medicine ER -